Navigation Links
How much is life worth? The $440 billion question
Date:7/3/2009

The decision to use expensive cancer therapies that typically produce only a relatively short extension of survival is a serious ethical dilemma in the U.S. that needs to be addressed by the oncology community, according to a commentary published online June 29 in the Journal of the National Cancer Institute.

Tito Fojo, M.D., Ph.D., of the Medical Oncology Branch, Center of Cancer Research at the National Cancer Institute, in Bethesda, Md., and Christine Grady, Ph.D., of the Department of Bioethics, the Clinical Center at the National Institutes of Health, tackle the controversy concerning the life-extending benefits of certain cancer drugs and the extent to which their cost should factor in deliberations.

The authors illustrate cost-benefit relationships for several cancer drugs, including cetuximab for treatment of non-small cell lung cancer, touted as "practice changing" and new standards of care by professional societies, including the American Society of Clinical Oncology.

They ask, "Is an additional 1.7 months [the additional overall survival for colorectal cancer patients treated with cetuximab] a benefit regardless of costs and side effects?"

According to Fojo and Grady, in the U.S., 18 weeks of cetuximab treatment for non-small cell lung cancer, which was found to extend life by 1.2 months, costs an average of $80,000, which translates into an expenditure of $800,000 to prolong the life of one patient by 1 year. At this rate, it would cost $440 billion annually, an amount 100 times NCI's budget, to extend the lives of 550,000 Americans who die of cancer annually by 1 year.

To address the issue, the commentators recommend that studies powered to detect a survival advantage of two months or less should test only interventions that can be marketed at a cost of less than $20,000 for a course of treatment.

Every life is of infinite value, the authors say, but spiraling costs of cancer care
'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
2. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
3. Biogenerics Will Save Billions, Says Hospira CEO
4. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
5. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
6. Entry of Biogenerics and Decreasing Use of Amgens Epogen and Johnson & Johnsons Procrit Will Cause a $2.8 Billion Decline in the Drug Market for Chemotherapy-Induced Anemia by 2016
7. Surgical and Trauma Wound Care Market to Tie Up $7 Billion in Sales by 2011
8. Foamix Signs Term Sheet to Acquire License to Organo-Boron Antifungal Molecules - Will Target the $11 Billion Dollars Fungal Infection Market
9. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
10. Sigma-Aldrich (Nasdaq: SIAL) Annual Sales Surpass $2 Billion Mark.
11. Medco Issues $1.5 Billion of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 During the ... now known as “The Doctor’s Plague.” In this time period, ... hands. This led, at times, to the death of vulnerable ... today don’t know that they may be unwittingly transmitting herpes ...
(Date:1/14/2014)... January 14, 2014 BioMedomics, Inc. , ... POC diagnostic platforms and novel disease specific POC tests, announced ... financing netting a total of $690,000. The investment is from ... the company. This group of private investors has significant successful ...
(Date:1/14/2014)... Translational Biosciences, a subsidiary of ... trial approval for the treatment of rheumatoid arthritis ... from the Comité Nacional de Bioética de la ... (RA) is an autoimmune disease in which the ...
Breaking Biology Technology:Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 3
... -- Sinovac Biotech Ltd.,(NYSE Alternext US: SVA), ... today,announced its wholly owned subsidiary, Tangshan Yian ... China,s Ministry of Agriculture to,conduct field trials ... with independent intellectual property rights. With this ...
... 26 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) ... efficacy portion of its initial Phase 3 clinical,trial evaluating ... acute treatment of migraine. , ... potential to be,both fast acting and long-lasting, providing pain ...
... second of its "next-generation" health and longevity products ... cardiovascular healthNEW YORK, Jan. 26 AIM Pharmakon, ... the introduction of the next generation of health ... premium-quality liquid calcium mineral concentrate for bone development ...
Cached Biology Technology:Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 2Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 3Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 4MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine 2MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine 3AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers 2AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers 3AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers 4
(Date:7/9/2014)... ability to switch out one gene for another in ... from science fiction to reality within this decade. As ... promise--the hope of fixing disease-causing genes in humans, for ... scientists have put one of those concerns to rest: ... overall occurrence of mutations in the cells. The new ...
(Date:7/9/2014)... Sexual selection refers to species, selection for traits ... type of natural selection enhances opportunities to mate, the ... Biologists at the University of California, Riverside have now ... of a placenta are linked. Describing the life ... the family Poeciliidae, the researchers found that species with ...
(Date:7/9/2014)... Cancer Genome Atlas (TCGA) Research Network have identified ... lung adenocarcinoma, the most common subtype of lung ... the number of possible therapeutic targets for this ... patients with treatable mutations because many potent cancer ... TCGA is jointly funded and managed by the ...
Breaking Biology News(10 mins):No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3
... from the Andes in Colombia to the Atlantic in ... plains of the Llanos and the Guiana shield ... 3rd most important river system on the planet, and one of ... has shown a strong commitment to the achievement of the ...
... citizens negotiated the tensions following the March 4 nationwide ... 2007 vote weighed heavily for many reasons. Among those ... of a new paper in AIDS Reviews , ... do to public health by disrupting treatment and thereby ...
... is an exotic plant originating from the Ukraine and ... Ontario, Canada. It has been found growing successfully in ... edges and understories, parks, road edges and railway embankments. ... large and dense stands that climb over other plants. ...
Cached Biology News:The natural ecosystems in the Colombian Orinoco Basin are in danger 2Political strife undermines HIV treatment 2Political strife undermines HIV treatment 3A European invader outcompetes Canadian plants even outside its usual temperature range 2
One-step, microplate or cuvet, colorimetric, detection range 0.78 ug/dL to 65 ug/dL Zn in serum, plasma, urine, saliva etc. Procedure: 10 min....
Zebrafish Ephrin-B2 Biotinylated Affinity Purified PAb...
... Customer Peptide Synthesis , Containing one Phospho-Amino Acid ... returned to customer conjugation of peptide to KLH protein , ... 102 days/each , Pre-immune bleed x1 /each ... Test bleed (app. 5 ml) x1 /each ...
The Varian 4000 GC/MS system offers three easily switchable ionization configurations: internal ionization (II), external ionization (EI) or hybrid chemical ionization (CI)...
Biology Products: